Good practices in Rituximab Administration: Integrative Literature Review

• Autor(a) principal: Rodrigues, Carmelita Almeida
• Data de Publicação: 2022
• Outros Autores: Lima, Maria Theresa Camilo de, De Domenico, Edvane Birelo Lopes
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/2194
• topic: rituximab/administração & dosagem; protocolos de quimioterapia combinada antineoplásica; protocolos antineoplásicos; rituximab/administration & dosage; antineoplastic combined chemotherapy protocols; antineoplastic protocols; rituximab/administración & dosificación; protocolos de quimioterapia combinada antineoplásica; protocolos antineoplásicos

Introduction: Rituximab is a mouse/human chimeric monoclonal antibody, widely used in the therapeutic setting of various diagnoses, due to its different administration, management and adverse effects protocols; its use requires attention by the healthcare team. Objective: Describe the infusion protocols for rituximab in the first, subsequent and desensitization infusions, and characterize their safety. Method: Integrative literature review. The search was performed in databases and electronic libraries: LILACS, PubMed, MEDLINE, SciELO and BDEnf. Results: In all, 413 articles were eligible after crossing the descriptors. Of these, 113 were read in full and eventually, 16 articles matched the study design. The articles were published from 2016 to 2020, predominantly in English (87.5%). Concerning the main routes of administration in the studies included, nine addressed the intravenous infusion (in different modalities of time) and seven, subcutaneously. Conclusion: According to the scientific literature, all intravenous and subcutaneous infusion modalities are shown to be safe and effective if the protocols are correctly selected and applied.